Baseline characteristics of the study population (N = 504)
| Characteristics . | ALFA-0702 LSC17 study (N = 504) . | |
|---|---|---|
| n or median . | % or range . | |
| Demographics and clinical variables | ||
| Age, y | 48 | 18-60 |
| Female | 237 | 47 |
| ECOG PS > 1 | 50 | 10 |
| Platelet count (109/L) | 67 | 4-1268 |
| WBC count (109/L) | 9 | 0.3-357.4 |
| ELN 2022 risk category | ||
| Favorable | 142 | 28 |
| Intermediate | 152 | 30 |
| Unfavorable | 205 | 41 |
| Unavailable∗ | 5 | 1 |
| Cytogenetics | ||
| Normal karyotype | 285 | 57 |
| Complex karyotype | 51 | 10 |
| Monosomal karyotype | 32 | 6 |
| del17p or 17p abnormality | 16 | 3 |
| t(9;11) | 7 | 1 |
| t(v;11) | 20 | 4 |
| Inv(3)/t(3;3) | 9 | 2 |
| t(6;9) | 7 | 1 |
| Missing karyotype | 6 | 1 |
| Gene mutations | ||
| NPM1 | 187 | 37 |
| In-frame bZIP CEBPA | 29 | 6 |
| FLT3-ITD | 119 | 24 |
| FLT3-TKD | 60 | 12 |
| RUNX1 | 54 | 11 |
| ASXL1 | 45 | 9 |
| TP53 | 30 | 6 |
| LSC17 score (continuous variable) | 0.60 | 0.06-1.40 |
| Characteristics . | ALFA-0702 LSC17 study (N = 504) . | |
|---|---|---|
| n or median . | % or range . | |
| Demographics and clinical variables | ||
| Age, y | 48 | 18-60 |
| Female | 237 | 47 |
| ECOG PS > 1 | 50 | 10 |
| Platelet count (109/L) | 67 | 4-1268 |
| WBC count (109/L) | 9 | 0.3-357.4 |
| ELN 2022 risk category | ||
| Favorable | 142 | 28 |
| Intermediate | 152 | 30 |
| Unfavorable | 205 | 41 |
| Unavailable∗ | 5 | 1 |
| Cytogenetics | ||
| Normal karyotype | 285 | 57 |
| Complex karyotype | 51 | 10 |
| Monosomal karyotype | 32 | 6 |
| del17p or 17p abnormality | 16 | 3 |
| t(9;11) | 7 | 1 |
| t(v;11) | 20 | 4 |
| Inv(3)/t(3;3) | 9 | 2 |
| t(6;9) | 7 | 1 |
| Missing karyotype | 6 | 1 |
| Gene mutations | ||
| NPM1 | 187 | 37 |
| In-frame bZIP CEBPA | 29 | 6 |
| FLT3-ITD | 119 | 24 |
| FLT3-TKD | 60 | 12 |
| RUNX1 | 54 | 11 |
| ASXL1 | 45 | 9 |
| TP53 | 30 | 6 |
| LSC17 score (continuous variable) | 0.60 | 0.06-1.40 |
ECOG PS, Eastern Cooperative Oncology Group performance status.
Karyotype data were missing for 3 patients, and the type of CEBPA mutation was missing for 2 patients.